GleamWall
中文EN

BJDX Bluejay Diagnostics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1704287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY119.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-138.1%
ROA-107.8%
ROIC (approx.)-1,839.1%
Asset turnover—

Leverage & solvency

Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.12M$1.44M$811,837$586,144$785,608$889,896$784,800$553,997
SG&A expense$944,845$911,318$1.13M$875,603$831,339$1.10M$1.10M$929,831
Operating income-$2.06M-$2.35M-$1.94M-$1.46M-$1.62M-$1.99M-$1.89M-$1.48M
Interest expense———$187$200$222—$15,231
Net income-$2.01M-$2.32M-$1.92M-$1.43M-$1.60M-$1.96M-$1.86M-$1.43M
EBITDA-$2.00M-$2.32M-$1.91M-$1.43M-$1.61M-$1.97M-$1.87M-$1.46M
EPS (basic)-1.72-1.12-1.95—-16.92-5.64-13.46—
EPS (diluted)-1.72-1.12-1.95—-16.92-5.64-13.46—
Weighted avg. shares (diluted)1.17M2.08M984,668—94,408346,780138,503—
Balance sheet
Cash & equivalents$7.38M$9.60M$3.68M$5.16M$3.08M$4.44M$3.12M$4.30M
Current assets$7.54M$9.81M$3.97M$5.46M$3.35M$4.75M$3.57M$4.90M
PP&E, net$1.78M$1.64M$1.53M$1.53M$1.39M$1.48M$1.50M$1.51M
Total assets$9.37M$11.53M$5.60M$7.12M$4.89M$6.40M$5.28M$6.66M
Current liabilities$1.93M$2.12M$1.41M$1.12M$1.15M$1.04M$1.32M$810,368
Total liabilities$1.93M$2.12M$1.42M$1.14M$1.20M$1.11M$1.41M$927,924
Shareholders' equity$7.44M$9.41M$4.18M$5.98M$3.69M$5.29M$3.87M$5.73M
Shares outstanding1.12M1.98M1.03M151,1331.64M1.49M554,012138,503
Cash flow statement
Operating cash flow-$2.00M-$1.50M-$1.59M-$1.45M-$1.36M-$2.05M-$1.18M-$1.45M
Capital expenditure$196,818$142,773$18,989————$1,125
Free cash flow-$2.20M-$1.64M-$1.61M————-$1.45M
Investing cash flow-$196,443-$142,773-$15,314————-$1,125
Financing cash flow-$19,530$7.56M$124,096$3.71M-$1,015$3.38M-$985-$1,326
Depreciation & amortization$61,922$28,193$27,763$27,415$10,624$17,742$18,401$19,775
Stock-based compensation$55,972——$74$183-$1,563$1,312-$2,582
Share buybacks$18,560———$0———

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.